Flu-Like Exhaustion and Brain Fog After Ejaculation: Post-Orgasmic Illness Syndrome (POIS), Explained
If ejaculation reliably triggers a 2-to-7-day flu-like crash—exhaustion, brain fog, muscle weakness, feverish warmth or nasal/eye irritation—clinicians recognise this pattern as Post-Orgasmic Illness Syndrome (POIS).
Short answer: If you reliably develop a flu-like crash—exhaustion, brain fog, feverish warmth, muscle weakness, itchy or burning eyes, nasal congestion or severe irritability—within seconds, minutes or a few hours of ejaculation, and it lasts for 2 to 7 days before disappearing on its own, clinicians recognise this pattern as Post-Orgasmic Illness Syndrome (POIS). First defined by Dutch neuropsychiatrist Marcel Waldinger in 2002 and listed as a rare condition by the US National Institutes of Health (NIH GARD ID 10809), POIS is a real physiological syndrome—not “sperm loss weakness” or an imaginary complaint.
Scope & clinical boundary: This explainer reviews the 5 published Waldinger diagnostic criteria, the 7 recognised symptom clusters, the competing immunological vs neuroendocrine hypotheses, and the clinical workup discussed in peer-reviewed urology and sexual-medicine literature (Waldinger, Translational Andrology and Urology 2016; Journal of Sexual Medicine systematic review 2025). It is not a personal diagnosis or a prescription protocol.
How POIS differs from normal post-sex sleepiness—and from “semen loss” myths
After orgasm, a brief wave of relaxation, warmth and drowsiness lasting 15 to 60 minutes is completely normal; it is driven by oxytocin, prolactin and parasympathetic nervous system rebound. By contrast, men with POIS experience a multi-day systemic illness that can make working, studying or driving difficult for nearly a week after a single ejaculation—whether that ejaculation occurred during partnered sex, solo masturbation or a spontaneous nocturnal emission (“wet dream”).
Because commercial supplement sellers and unmoderated forums often blame any post-ejaculation fatigue on “vitality loss” or masturbation-induced weakness, many adults with genuine POIS spend years taking useless herbal tonics instead of seeing a urologist, immunologist or sexual-medicine specialist. Distinguishing POIS starts with checking the five clinical criteria used in research worldwide.
The 5 Waldinger diagnostic criteria and 7 symptom clusters
Based on clinical cohorts in the Netherlands and subsequent international studies (Waldinger 2016; PMC11662807, 2024), researchers evaluate suspected POIS against five preliminary criteria and seven distinct symptom clusters.
| Criterion or cluster | Clinical requirement in published POIS studies | How it separates POIS from other conditions |
|---|---|---|
| Criterion 1: Symptom profile (≥1 of 7 clusters) | Cluster 1 (General): extreme fatigue, palpitations, word-finding difficulty, poor concentration, irritability, noise/light sensitivity, low mood. Cluster 2 (Flu-like): feverish sensation, sweating, shivering, feeling cold or ill. Cluster 3 (Head): headache, heavy or “foggy” head. Cluster 4 (Eyes): burning, red, watery or itchy eyes, blurred vision. Cluster 5 (Nose): nasal congestion, runny nose, sneezing. Cluster 6 (Throat): sore throat, dry mouth, hoarse voice, ticklish cough. Cluster 7 (Muscle): heavy, tense, weak or stiff neck, back or leg muscles. |
Unlike postcoital dysphoria (which is purely emotional sadness/tearfulness for minutes to hours) or benign sex headaches, POIS combines cognitive, systemic flu-like, mucosal and muscular symptoms. |
| Criterion 2: Rapid onset clock | Symptoms begin immediately (within seconds), within minutes, or within a few hours after ejaculation—triggered by intercourse, masturbation or spontaneous nocturnal emission. | Separates POIS from infectious viral illnesses or STI incubations, which do not switch on within minutes of every solo or partnered ejaculation. |
| Criterion 3: High consistency (>90% rule) | Symptoms occur always or nearly always (in more than 90% of ejaculation events). | Rules out situational exhaustion from late-night activity, alcohol, dehydration or occasional vigorous exercise. |
| Criterion 4: Multi-day duration (2–7 days) | Most symptoms persist for 2 to 7 days, typically peaking on Day 1 or Day 2 after ejaculation. | Separates POIS from normal post-orgasmic refractory sleepiness (which resolves within an hour or after a night’s sleep). |
| Criterion 5: Spontaneous resolution | Symptoms disappear completely on their own after 2–7 days until the next ejaculation triggers the cycle again. | Distinguishes POIS from chronic fatigue syndrome (ME/CFS), chronic depression or persistent medication side effects (such as PSSD). |
Clinicians also classify POIS into two onset patterns:
- Primary POIS: Present from the very first ejaculations in puberty or adolescence.
- Secondary POIS: Develops later in adulthood after years of normal, symptom-free ejaculations—sometimes following a pelvic infection, urological procedure or hormonal shift.
What causes POIS? The two competing medical hypotheses
As a 2025 systematic review in the Journal of Sexual Medicine (J Sex Med 2025;22(7):1236) notes, the exact pathophysiology of POIS remains under active investigation, with two main mechanisms proposed in peer-reviewed studies:
- The autologous seminal-fluid immunologic / allergic hypothesis (Waldinger hypothesis): Waldinger proposed that during ejaculation, microscopic antigens or peptides from the person’s own seminal fluid (produced by the prostate, seminal vesicles or testes) contact the mucosal lining of the urethra and trigger a combined Type I (immediate IgE/histamine) and Type IV (delayed T-cell cytokine) hypersensitivity reaction. In Waldinger’s Dutch cohort, 88% of tested men showed a positive wheal-and-flare skin-prick reaction to their own diluted semen, though later Korean and international studies noted that healthy control men can also show skin reactivity to autologous semen.
- The neuroendocrine / endogenous opioid-withdrawal and autonomic hypothesis: Other researchers point out that POIS can persist even after a vasectomy, can occur in rare female cases, and is sometimes triggered by intense sexual arousal or non-ejaculatory orgasm. This hypothesis suggests that an abrupt drop in endogenous μ-opioids, dopamine or progesterone/testosterone signalling—or sympathetic-parasympathetic nervous system dysregulation—triggers acute neurogenic inflammation, histamine release and cognitive fog.
Differential diagnosis and treatments studied in clinical literature
Because there is no single commercial blood test for POIS, no medicine holds a specific FDA, EMA or MHRA license for the condition. Instead, sexual-medicine specialists first rule out treatable endocrine or urological mimics, and then trial targeted symptom-blocking strategies documented in case series and systematic reviews (J Sex Med 2025; Takeshima et al., IJU Case Reports 2020).
| Clinical step or off-label class studied | Mechanism targeted | Evidence level & important clinical caveats (checked 22 October 2026) |
|---|---|---|
| 1. Baseline endocrine & urological workup | Rules out late-onset hypogonadism (low morning total/free testosterone), thyroid disease, hyperprolactinaemia, vitamin D deficiency and chronic prostatitis/chronic pelvic pain syndrome (CPPS). | Essential first step: Case reports (Takeshima et al. 2020) document complete or major resolution of secondary POIS when underlying testosterone deficiency was identified and corrected. |
| 2. Pre-ejaculation NSAIDs (e.g., diclofenac, celecoxib, ibuprofen) | Blocks prostaglandin synthesis and acute cytokine-mediated flu-like inflammation when taken 1–2 hours before planned sexual activity. | Case series & clinical reports: Works best for the flu-like, headache and myalgia clusters in a subset of patients; requires gastro-renal safety screening by a doctor and cannot be taken daily without supervision. |
| 3. Non-sedating H1 antihistamines (or mast-cell / IgE biologics) | Targets histamine-driven nasal congestion, watery/burning eyes and flushing; rare refractory cases have trialled anti-IgE therapy (omalizumab). | Case reports (PMC11662807, 2024): Antihistamines are low-risk to discuss with a GP or allergist; biologics like omalizumab remain experimental case-report options. |
| 4. Selective alpha-1A blockers (e.g., silodosin) | Prevents seminal emission into the posterior urethra during orgasm (creating dry/retrograde orgasm) to test whether urethral semen contact is the trigger. | Small prospective cohorts: Reduces symptoms in men whose POIS is strictly triggered by urethral seminal fluid passage, though it causes reversible dry orgasms while taken. |
| 5. Autologous semen hyposensitisation / intralymphatic immunotherapy | Repeated subcutaneous or intralymphatic micro-injections of highly diluted autologous semen over months to years to build immunologic tolerance. | Experimental specialist protocol: Reported by Waldinger and small allergy-clinic cohorts, but requires sterile laboratory preparation and anaphylaxis precautions; not a standard community treatment. |
How to prepare for a doctor or urologist appointment
Many general practitioners have never encountered POIS in clinic and may initially confuse it with anxiety or chronic prostatitis. To get a productive evaluation:
- Keep a 4-week symptom log: Record the exact time of each ejaculation (partnered, solo or nocturnal), the time each symptom cluster starts, its peak severity (1–10), and the day it clears.
- Bring a printed peer-reviewed summary: Print or save the NIH GARD entry (`GARD 10809`) and Waldinger’s 5 criteria (PMC5001999) so your clinician can review the medical literature directly.
- Ask for a baseline hormone and metabolic panel: Request an early-morning fasting total and free testosterone, LH, FSH, prolactin, TSH, full blood count and inflammatory markers before trialling any off-label pre-medication.
- Protect relationship communication: Many men with POIS quietly avoid sex or schedule intimacy only before weekends to hide the multi-day crash, leaving partners feeling rejected. Explaining the 2–7 day physiological window—and exploring non-ejaculatory intimacy when desired—removes blame on both sides. See our Talk to a Real Clinician directory for sexual-medicine and urology society finders.
Method, scope and sources
This article synthesises peer-reviewed clinical cohorts, case reports and systematic reviews on Post-Orgasmic Illness Syndrome, checked 22 October 2026:
- Waldinger MD. Post orgasmic illness syndrome (POIS). Translational Andrology and Urology. 2016;5(4):602–606 (checked 22 October 2026).
- Oxford Academic / ISSM. Treatments for postorgasmic illness syndrome: a systematic review. The Journal of Sexual Medicine. 2025;22(7):1236 (checked 22 October 2026).
- National Center for Biotechnology Information (PMC). Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report. 2024 (checked 22 October 2026).
- Takeshima T, et al. Case of post-orgasmic illness syndrome associated with hypogonadism. IJU Case Reports. 2020;3(5):189–191 (checked 22 October 2026).
- National Center for Biotechnology Information (PMC). The first Tunisian case of postorgasmic illness syndrome: A case report. Urology Case Reports. 2021 (checked 22 October 2026).
